Dynamic evolution and antitumor mechanisms of CXCR6CD8 T cells in small cell lung cancer treated with low-dose radiotherapy and immunotherapy.
作者信息
Lin Guo, Yao Zhuoran, Kang Kai, Luo Ren, Yi Linglu, Lu You
机构信息
Division of Thoracic Tumor Multimodality Treatment and Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Laboratory of Clinical Cell Therapy, West China Hospital, Sichuan University, Chengdu, China.
出版信息
J Transl Med. 2025 Apr 17;23(1):453. doi: 10.1186/s12967-025-06450-1.
BACKGROUND
Patients with small-cell lung cancer (SCLC) have the poor prognosis. Current research suggested that low-dose radiotherapy (LDRT) combined with immunotherapy can enhance the immunogenicity of tumor cells, thereby improving antigen presentation and promoting the intratumoral infiltration of CD8 T cells, which significantly extends the survival of patients. However, the change trajectory of T cells, and the mechanisms underlying the promotion of intratumoral infiltration of CD8 T cells, and the enhancement of their cytotoxic functions remain to be elucidated.
METHODS
To delineate the dynamic changes of T cells, we collected tumors from Kaede tumor-bearing mice that had undergone radioimmunotherapy. Using flow cytometry, we sorted intratumoral-infiltrating immune cells, which were required for single-cell RNA sequencing, at various time points (Kaede Red: derived from tumor-draining lymph node [TDLN]). The results obtained from the sequencing analysis were further validated through experiments, such as flow cytometry, immunofluorescence, and analysis of clinical cohort data.
RESULTS
Here, we observed stem-like T cells migrating from the TDLN to the tumor site and differentiating into effector phenotypes within the tumor. Dendritic cells (DCs) are the key cluster that induces the differentiation of stem-like T cell into effector phenotypes. Moreover, SCLC patients with a high infiltration of tumor-specific CXCR6CD8 T cells exhibited a supportive TME and longer survival time (P < 0.001).
CONCLUSIONS
This study delineates the change trajectory of CD8 T cells, identifies the crucial role of DCs in T cell differentiation, and highlights the significance of tumor-specific CXCR6CD8 T cells in anti-tumor immunity. Future therapeutic strategies for SCLC could focus on enhancing the infiltration of activated DCs and CXCR6CD8 T cells within the tumor microenvironment to improve treatment efficacy.
相似文献
J Immunother Cancer. 2021-8
引用本文的文献
Nat Rev Urol. 2025-8-27
本文引用的文献
Nat Rev Clin Oncol. 2024-8